Transdermal Delivery Systems2011
Transdermal Delivery Systems2011
Systems
Advantages of Transdermal
Delivery Systems
Reasonably constant dosage can be maintained
(as opposed to peaks and valleys associated
with oral dosage)
First pass metabolism in the liver and GI tract is
avoided
Reduced need for active administration (some
patches can last 7 days)
The patch is noninvasive and dosage can be
stopped by removal
Easy to apply and to monitor
Oral versus Transdermal
EE = Ethinyl Estradiol
Limitations of Transdermal Delivery
Systems
Film Backing
Drug/Adhesive Layer
skin
Drug in Adhesive Patches Can Also Have
Additional Layers to Regulate Rate of Drug
Delivery
Link
Reservoir Patches
Film Backing
Drug Layer
Rate-controlling Membrane
Contact Adhesive
skin
Article illustrating two types of patches can be found at:
http://molinterv.aspetjournals.org/cgi/reprin
t/4/6/308
What kind of drugs can be
incorporated into a patch?
Compounds with low logP will not diffuse
into skin lipids
However, compounds with high logP also
have difficulties, this time associated with
their diffusion out of the stratum corneum.
The accepted range of logP values is
between 1 and 3.
Products on the market, or in development include:
Clonidine
Works as an agonist of adrenaline at the
presynaptic 2 adrenergic
Product name = Catapres-TTS
used to treat hypertension
Ethinylestradiol (EO) and norelgestromin (N)
Product name = Ortho-Evra
Used for Contraception
Type of patch = Drug-in-Adhesive
Frequency of application = weekly
Fentanyl
Product Name = Duragesic
Used for: Analgesia
Type of Patch = Drug-in-Adhesive
Frequency of Application = Weekly
Lidocaine
Product Name = Lidoderm
Used for: analgesia of postherpetic neuralgia
(PHN), a painful condition caused by the
varicella zoster virus (herpes zoster = shingles)
Lidoderm Patch
LINK
The microneedle technology can result in more effective contact of the vaccine
with the antigen-presenting Langerhans cells
LINK
Assigned Reading
Scheindlin Stanley Transdermal drug delivery: PAST,
PRESENT, FUTURE. Molecular interventions (2004), 4(6),
308-12 (see link in presentation).
Prausnitz, Mark R.; Langer, Robert. Transdermal drug
delivery. Nature Biotechnology (2008), 26(11), 1261-1268
Link
Sieg, A.; Wascotte, V. Diagnostic and therapeutic applications
of iontophoresis. Journal of Drug Targeting, (2009); 17(9):
690-700.
Graduate Students Only: Subedi, R. K. et al. Recent
Advances in Transdermal Drug Delivery. Archives of Pharmal
Research (2010), 33(3): 339-351.
Homework Questions
1. List the advantages of administering drugs via trandermal drug delivery
systems, over administering medications orally.
2. Use diagrams to illustrate the differences between a drug-in-adhesive patch
and a reservoir patch
3. List the limitations on the types of drugs which can be administered by first-
generation transdermal delivery systems. Explain why much of the drug is
wasted, and how this is commercially feasible.
4. Draw the structures of the following drugs and circle the functionalities
capable of ionization at biological pH. Redraw each structure, showing the
predominant charge state at pH = 7.4 (blood pH): Fentanyl, Lidocaine.
5. Explain how second and third generation transdermal devices differ from
first generation and provide examples of each that are in clinical trials.
6. Explain how transdermal delivery of vaccines might elucidate a greater
immune response than conventional methods.